3SOF

Keeps appearing on the Market Movers List and no wonder. Right at resistance area now but interestingly the volume keeps increasing on each days action. Historically has made a move from $3 to $7 before in relative short space of time, overextended no doubt but sometimes that just doesn't stop em.
Something is driving this action, I don't know what but it is.
On my to do list...
Mike

to me, OSCI looks good to go

any opinions ? 

thank you

I'm seeing very low volume on osci for such a low priced stock.   If you are interested in this industry, have a look at HGSI. If it can push its way past the resistance at 11.68, might be a fun ride.  I'm in as of yesterday at 11.28.  We'll see how it goes.

FYI,  I am mostly a trader, in and out in no more than 2 days.


good karma to all,

Heidi

I bought this one today at $2.50

They are introducing FASTIVE, the latest fluroquinone antibiotic and have rampped up their sales force and it is rolling out.

But the big reason I bought is they are in the late Phase ll trial  for Ramplanin, their anwser to VPHM's Vancocin. In studies to date, it appears just as good and may hit Vancocin resistant strains of C Difficlie. The OSCI drug will be a 2 times per day dose vs 4 times a day for Vancocin.That is a big + with patient compliance.

SO are 76 Million and Float is 75 Million

It is above its 50 day MA and possibly appraching a Golden Bullish Cross.

They have a lot of cash 125 Million and debt of $175 Million. I need to dig more into this so I just nibbled for now.

I look at companies like this as still start ups. But as FASTIVE gains footing and Ramplanin can come on stream, well you see what happened to VPHM. I know most of you are traders and I do not think this may fit that mold. However, I like its prospects.

I spoke to the company Lab person about the testing results and also to the IR person about FASTIVE to verify what i had read in what was published.

John

Hi,

time to buy...
Buy at 1.930
target at 2.610
stop at 1.610

news :
WALTHAM, Mass., Oct 31, 2005 (BUSINESS WIRE) -- - Four poster presentations highlighting data from Oscient Pharmaceuticals' (OSCI) FDA-approved fluoroquinolone antibiotic, FACTIVE(R) (gemifloxacin mesylate) tablets, are being presented at CHEST 2005, the Annual Meeting of the American College of Chest Physicians (ACCP). Included in the program are data exploring the clinical activity of FACTIVE in treating acute bacterial exacerbations of chronic bronchitis (AECB), community-acquired pneumonia (CAP) in patients with risk factors and co-morbidities and respiratory tract infections caused by resistant bacteria. ...

WALTHAM, Mass., Nov 02, 2005 (BUSINESS WIRE) -- Oscient Pharmaceuticals Corporation (OSCI) today reported financial results for the third quarter ended September 30, 2005. During this period, the Company recorded $5.9 million in total revenue, with $4.8 million from the Company's lead product, FACTIVE (R) (gemifloxacin mesylate) tablets, FDA-approved for the treatment of acute bacterial exacerbations of chronic bronchitis (AECB) and mild to moderate community-acquired pneumonia (CAP). FACTIVE revenues reflect sales of the product during the third quarter as well as the recognition of revenue from product shipped during prior periods. The Company also recorded more than $1.1 million in revenue from the Company's co-promotion agreement with Auxilium Pharmaceuticals for TESTIM(R) 1% testosterone gel. ...

is reviewing Factive....

Yes or Not ?

Wait'n'see...

http://finance.yahoo.com/q?s=osci

ooops,

UPDATE 1-US panel rejects Oscient antibiotic for sinusitis 

Oscient Pharmaceuticals and Menarini Group Enter into European Commercialization Agreement for FACTIVE Tablets
BusinessWire - January 04, 2007 8:30 AM ET
 
Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) has granted the commercialization rights to FACTIVE(R) (gemifloxacin mesylate) tablets in Europe to Menarini Group, a leading European pharmaceutical company based in Italy. Menarini, with broad sales and marketing coverage throughout Europe, has the fourth largest pharmaceutical sales force in Europe and is second largest in terms of calls to primary care physicians.

"With this agreement, we have successfully granted FACTIVE commercialization rights in all of our licensed territories to leading pharmaceutical companies - a key step in building FACTIVE as a global brand," stated Steven M. Rauscher, President and Chief Executive Officer of Oscient Pharmaceuticals. "Menarini, with regulatory and marketing expertise that has helped build a portfolio of 57 products, is one of the fastest growing pharmaceutical companies in Europe and is extremely well-positioned to pursue approval and launch FACTIVE into the European market."

In exchange for European rights, Menarini has agreed to make an upfront payment, as well as a series of payments upon achievement of regulatory, reimbursement and sales milestones. In addition, Menarini will pay Oscient for product supply at a transfer price that includes product costs and compensation to Oscient. Menarini will pursue European regulatory approval in coordination with Oscient and will have access to the clinical trial dossier for FACTIVE and the post-marketing data from use in the U.S. market. As part of the regulatory collaboration, Oscient will reimburse Menarini for regulatory expenses up to an agreed limit. Additional financial terms were not disclosed.

Oscient licensed the rights to commercialize FACTIVE in North America and Europe from LG Life Sciences. As recently announced, Oscient has restructured its license agreement with LG Life Sciences to include over 40 countries in Europe, including all of the current members of the European Union. The antibiotic market in Europe is estimated at $5 billion, with France, Germany, Italy and Spain representing the largest markets. FACTIVE is not currently approved for use in Europe. In 2006, Oscient forged partnerships for the commercialization of the drug in Mexico and Canada. Pfizer, S.A. de C.V. has launched FACTIVE in Mexico and Abbott Canada is planning to launch FACTIVE in Canada early this year.

 Oscient To Also Get Royalty, Other Pay From Menarini  Dow Jones Newswires
8:43 am Oscient To Get Upfront Payment For Menarini Grp Dow Jones Newswires
8:42 am Oscient Grants Commcl Rights To Factive To Menarini Grp Dow Jones Newswires

Up with huge volume on 12/29/2006. Bottom reverse is likely from its weekly chart. MA15 becomes a support rather than resistance. High revenue growth. 

What do you guys think?

Potential short !

"OSCI" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.                                       
All history on a stock pick in 1 thread is awesome.                                    
Just trying to get threads together,so we don't have a numerous amount floating around on the same stock.                
Thank You....and good luck with all your trades....make some $$$